Literature DB >> 32839214

Collagen Density Modulates the Immunosuppressive Functions of Macrophages.

Anne Mette H Larsen1,2, Dorota E Kuczek1, Adrija Kalvisa3, Majken S Siersbæk3, Marie-Louise Thorseth1, Astrid Z Johansen1,4, Marco Carretta1, Lars Grøntved3, Ole Vang2, Daniel H Madsen5,4.   

Abstract

Tumor-associated macrophages (TAMs) support tumor growth by suppressing the activity of tumor-infiltrating T cells. Consistently, TAMs are considered a major limitation for the efficacy of cancer immunotherapy. However, the molecular reason behind the acquisition of an immunosuppressive TAM phenotype is not fully clarified. During tumor growth, the extracellular matrix (ECM) is degraded and substituted with a tumor-specific collagen-rich ECM. The collagen density of this tumor ECM has been associated with poor patient prognosis but the reason for this is not well understood. In this study, we investigated whether the collagen density could modulate the immunosuppressive activity of TAMs. The murine macrophage cell line RAW 264.7 was three-dimensionally cultured in collagen matrices of low and high collagen densities mimicking healthy and tumor tissue, respectively. Collagen density did not affect proliferation or viability of the macrophages. However, whole-transcriptome analysis revealed a striking response to the surrounding collagen density, including the regulation of immune regulatory genes and genes encoding chemokines. These transcriptional changes were shown to be similar in murine bone marrow-derived macrophages and TAMs isolated from murine tumors. Strikingly, coculture assays with primary T cells showed that macrophages cultured in high-density collagen were less efficient at attracting cytotoxic T cells and capable of inhibiting T cell proliferation more than macrophages cultured in low-density collagen. Our study demonstrates that a high collagen density can instruct macrophages to acquire an immunosuppressive phenotype. This mechanism could reduce the efficacy of immunotherapy and explain the link between high collagen density and poor prognosis.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32839214     DOI: 10.4049/jimmunol.1900789

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.

Authors:  Azam Bozorgi; Maryam Bozorgi; Mozafar Khazaei
Journal:  Cell Oncol (Dordr)       Date:  2022-08-09       Impact factor: 7.051

Review 2.  Innate Immunity and Cancer Pathophysiology.

Authors:  Laura Maiorino; Juliane Daßler-Plenker; Lijuan Sun; Mikala Egeblad
Journal:  Annu Rev Pathol       Date:  2021-11-17       Impact factor: 32.350

3.  Tissue density in the progression of breast cancer: Bedside to bench and back again.

Authors:  Emily Fabiano; Jian Zhang; Cynthia A Reinhart-King
Journal:  Curr Opin Biomed Eng       Date:  2022-03-28

Review 4.  Incorporating Tumor-Associated Macrophages into Engineered Models of Glioma.

Authors:  Erin A Akins; Manish K Aghi; Sanjay Kumar
Journal:  iScience       Date:  2020-11-05

Review 5.  ADAMTS proteases and the tumor immune microenvironment: Lessons from substrates and pathologies.

Authors:  Silvia Redondo-García; Carlos Peris-Torres; Rita Caracuel-Peramos; Juan Carlos Rodríguez-Manzaneque
Journal:  Matrix Biol Plus       Date:  2020-12-30

Review 6.  Multicellular 3D Models to Study Tumour-Stroma Interactions.

Authors:  Elisabetta Colombo; Maria Grazia Cattaneo
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 7.  Macrophage-stroma interactions in fibrosis: biochemical, biophysical, and cellular perspectives.

Authors:  Gwenda F Vasse; Mehmet Nizamoglu; Irene H Heijink; Marco Schlepütz; Patrick van Rijn; Matthew J Thomas; Janette K Burgess; Barbro N Melgert
Journal:  J Pathol       Date:  2021-03-03       Impact factor: 7.996

Review 8.  Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.

Authors:  Nicholas Willumsen; Christina Jensen; George Green; Neel I Nissen; Jaclyn Neely; David M Nelson; Rasmus S Pedersen; Peder Frederiksen; Inna M Chen; Mogens K Boisen; Astrid Z Johansen; Daniel H Madsen; Inge Marie Svane; Allan Lipton; Kim Leitzel; Suhail M Ali; Janine T Erler; Daan P Hurkmans; Ron H J Mathijssen; Joachim Aerts; Mohammed Eslam; Jacob George; Claus Christiansen; Mina J Bissel; Morten A Karsdal
Journal:  Cell Mol Life Sci       Date:  2022-03-25       Impact factor: 9.207

Review 9.  Chronic Diabetic Wounds and Their Treatment with Skin Substitutes.

Authors:  Jordan Holl; Cezary Kowalewski; Zbigniew Zimek; Piotr Fiedor; Artur Kaminski; Tomasz Oldak; Marcin Moniuszko; Andrzej Eljaszewicz
Journal:  Cells       Date:  2021-03-15       Impact factor: 6.600

10.  Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth.

Authors:  Nancy D Ebelt; Vic Zamloot; Edith Zuniga; Kevin B Passi; Lukas J Sobocinski; Cari A Young; Bruce R Blazar; Edwin R Manuel
Journal:  Cancers (Basel)       Date:  2021-07-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.